Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.

Abstract

We assessed concentrations of arsenic trioxide (As(2)O(3)) and its metabolites in the plasma and cerebrospinal fluid in acute promyelocytic leukemia patients who achieved complete remission with intravenous As(2)O(3). Arsenic trioxide exists as high molecular mass proteins and low molecular mass proteins in the plasma, and metabolites seem to be able to penetrate blood-brain barrier. Methylarsonic acid (MA) in the cerebrospinal fluid is stably detected and its level was higher than that in plasma after As(2)O(3) treatment. Trivalent arsenic (AS(III)) and dimethylarsinic acid (DMA) became detectable after As(2)O(3) infusion, though the levels of arsenic metabolites in the cerebrospinal fluid was lower than plasma levels. Results suggest that a combinatory treatment of As(2)O(3) with other chemotherapeutics could be effective for APL patients with CNS involvement.

• Authors: Toru Kiguchi, Yuta Yoshino, Bo Yuan, Seiichiro Yoshizawa, Toshihiko Kitahara, Daigo Akahane, Moritaka Gotoh, Toshikazu Kaise, Hiroo Toyoda, Kazuma Ohyashiki
• Journal: Leukemia research (Leuk Res) Vol. 34 Issue 3 Pg. 403-5 (Mar 2010) ISSN: 1873-5835 [Electronic] England
• PMID: 19733394 (Publication Type: Journal Article)
• Copyright: Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents
• Arsenicals
• Oxides
• Arsenic Trioxide

Topics

• Adult
• Antineoplastic Agents (blood, cerebrospinal fluid, therapeutic use)
• Arsenic Trioxide
• Arsenicals (blood, cerebrospinal fluid, therapeutic use)
• Chromatography, High Pressure Liquid
• Female
• Humans
• Leukemia, Promyelocytic, Acute (blood, cerebrospinal fluid, drug therapy)
• Male
• Middle Aged
• Oxides (blood, cerebrospinal fluid, therapeutic use)